anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
@ A microprocessor-controlled interface for permitting any digital host computer to receive serial digital data from any instrument wherein (a) the time at which digital data from the instrument is to enter the host computer and (b) the logical structure of the digital data entering the host computer are controlled by instructions from the host computer to the microprocessor and wherein (a) physical formatting incompatibilities between the host computer and the instrument and (b) the communicating of prohibited characters from the instrument to the host computer and vice versa are avoided. The timing control and logical structure of the digital data are effected by directing data from the instrument into a scratchpad memory, which is divided into records pursuant to instructions from the host computer, the contents of the scratchpad memory being sent to the host computer upon a corresponding instruction therefrom. A terminal for communicating with the host computer and the instrument may be included. Physical formatting discrepancies are avoided by translating inputs to the interface into a common physical format and translating outputs from the interface into the physical format of the instrument, host computer, or terminal which is receiving such outputs. Because about 90% of all current digital devices are formatted in a manner translatable by a selected one of three translator elements, a small number of interfaces formatted for a specific host computer (and terminal) can be used with a vast number of different instruments by accounting only for the instrument physical format and associated prohibited characters. Instructions, selected from a set of distinct instructions, which are sent from the computer to the microprocessor determine (a) whether a terminal-host computer, instrument-host computer, or terminal-instrument communication channel is to be open, (b) whether all channels are to be closed, and (c) when other communication transfer operations are to be executed. Terminal-host computer communications can occur at least substantially simultaneously with the directing of digital data from the instrument to the scratchpad memory.
This is an observational, retrospective, single-centered study using clinical data from the patient's medical record from the hospital, the national prescription database of the Directorate of Health, and the ICD-10 codes from primary care records. For this analysis, medicines will be classified into drug classes based on the first five characters of their WHO Anatomical Therapeutic Chemical (ATC) code. The prevalence (pre) and incidence (post) of polypharmacy (≥5 or more regular medicines) and hyper-polypharmacy (≥10 regular medicines) will be calculated. Potentially inappropriate prescribing will be assessed in individuals ≥65 years, applying Beers 2019, Start and Stopp 2014, explicit prescribing criteria. The analysis will be restricted to older individuals, as Beers criteria have not been validated in younger age groups. The anticholinergic burden will be assessed for all individuals ≥18 years will be assessed by applying the anticholinergic burden scale, and the PRIME tool will be applied to predict the likelihood of medication-related harm post-discharge. The PRIME tool consists of eight variables drawn from clinical, medication, and psychosocial domains. Applied at the point of discharge, it provides the absolute risk of an individual older adult experiencing medication-related harm during the eight weeks after discharge from acute hospital admission. This stratification is important in order to deliver targeted interventions in resource-limited healthcare settings.
Although progress has been made in the treatment of cancer, particularly for the four major types of cancers affecting the lungs, colon, breast and prostate, resistance to cancer treatment often emerges upon inhibition of major signaling pathways, which leads to the activation of additional pathways as a last-resort survival mechanism by the cancer cells. This signaling plasticity provides cancer cells with a level of operational freedom, reducing treatment efficacy. Plasticity is a characteristic of cancer cells that are not only able to switch signaling pathways but also from one cellular state (differentiated cells to stem cells or vice versa) to another. It seems implausible that the inhibition of one or a few signaling pathways of heterogeneous and plastic tumors can sustain a durable effect. We propose that inhibiting molecules with pleiotropic functions such as cell surface co-receptors can be a key to preventing therapy escape instead of targeting bona fide receptors. Therefore, we ask the question whether co-receptors often considered as "accessory molecules" are an overlooked key to control cancer cell behavior.
Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 CAR-T cells and the investigators will determine the safety and therapeutic effects of these cells.
The PI group consisted of 23 patients (9M/14F) with ages ranging from 29 to 66 years (mean 51,91 ± 10,63). This group was selected based on the success criteria of Misch et al. 2008; patients with clinical findings such as bleeding and/or sweeping in their implants, pain or tenderness during function, and exudation in peri-implant tissues, with at least 1 implant with a pocket depth of more than 7 mm and radiographic bone loss of at least 4 mm or more around the implant were included.
FIELD: medicine, stomatology. SUBSTANCE: invention relates to agents used for treatment of teeth hypersthesia and caries prophylaxis. Agent is made in the form of biocompatible polymeric film involving the combined hydrophilic and hydrophobic layers. Hydrophilic layer has one or more sources of fluoride ions and antibacterial preparations. Agent has inorganic water-soluble fluorides of type MF, MF 2 , MF 3 , MF 4 , mixtures of inorganic fluorides of type MF x  with MF y , organic fluorine-containing compounds and mixture of inorganic and organic fluorides as the source of fluoride ions. Agent has a plasticizer, prolonging substances and pH regulating components additionally. Agent shows anticaries and antibacterial effect and provides delivery of dosed amount of fluoride ions. EFFECT: improved and valuable medicinal properties of agent. 9 cl
Cardiovascular disease is the leading cause of death for women. Acute coronary syndrome (ACS) is usually characterized by a sudden erosion of the endothelial wall or rupture of a plaque.However, women with ACS are less likely than men to have either classic symptoms or obstructive coronary artery disease but paradoxically have a worse prognosis. Different data from the literature indicate that there may be different pathophysiological mechanisms, afflicting men and women somewhat differently.Between 5% and 30% of patients with ACS undergoing coronary angiography are found to have non visible or non obstructive coronary disease (NOCD). This is 2-3 times more common in women than in men. Several pathogenetic mechanism of myocardial infarction (MI) in the absence of obstructive coronary artery disease (OCD) have been postulated, including among others atherosclerosis with plaque disruption that does not lead to luminal occlusion ,endothelial dysfunction, vasospasm , distal microembolization and microvascular dysfunction. However the data are extremely limited.
This invention provides an isolated nucleic acid molecule which encodes a wildtype or mutated HOP-1. This invention also provides a purified wild-type HOP-1 protein or a purified mutated HOP-1 protein. This invention also provides a method for production of an antibody capable of binding to wild-type HOP-1 or mutated HOP-1 protein. This invention also provides an antibody capable of specifically binding to wild-type HOP-1 or mutated HOP-1. This invention also provides a transgenic animal comprising the isolated nucleic molecule encoding HOP-This invention also provides Caenorhabditis elegans mutants in the endogenous hop-1 gene and various method to produce such mutants. This invention also provides a method for identifying a compound which is capable of ameliorating Alzheimer's disease. This invention also provides a method for determining whether a compound is capable of ameliorating Alzheimer's disease. This invention also provides a method for producing suppressors of a hop-1 allele. This invention also provides a pharmaceutical composition effective in ameliorating Alzheimer's disease and methods of using such a pharmaceutical composition.
Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.
DentalVibe® Comfort Injection System will be used prior and during the local anesthesia (LA) injection for inferior alveolar nerve (IAN) block. The LA to be used is Lidocaine 2% with Epinephrine dental injection.
PURPOSE: A pharmaceutical formulation containing, as an effective ingredient, an extract for promoting the growth of a mammal extracted from natural drugs such as Acanthopanax Senticosus(Rupr. et Maxim.) Harms, etc. is provided. The formulation has no toxicity and excellent growth promotion activity and is thus effectively used in treatment and prevention of homunculus, dwarfism and failure to thrive syndrome of children and infants. CONSTITUTION: The pharmaceutical formulation contains a growth promotion extract and a pharmaceutically acceptable excipient. The growth promotion extract is obtained from 10 to 99% by weight of Acanthopanax Senticosus, 0.1 to 60% by weight of Rehmanniae Radix Preparata, 0.1 to 60% by weight of Dioscoreae Rhizoma, 0.1 to 60% by weight of Corni Fructus, 0.1 to 60% by weight of Poria cocos, 0.1 to 60% by weight of Cervi cornu and 0.1 to 60% by weight of Ginseng Radix.
Patients with osteoarthritis were randomly allocated into two groups. Group I (n=26) received intra-articular injection of 7 mL 0.5% lidocaine and Group II (n=26) received 7 mL saline into painful knee for 3 times with one week intervals under USG guidance. VAS and WOMAC scale including pain, stiffness and physical function was used for the assessment of patients with osteoarthritis. Analgesic requirements were also recorded.

The primary outcome parameter of this study was the pain scores. The sample size for the primary variable was calculated based on a standard deviation of 20 mm estimated from a previous study. A power analysis with a type II error of 20% at a two-sided 5% significance level estimated 22 patients per group to be included. Investigators included 26 patients per groups for possible missing date. χ2 test for categorical data and independent samples t-test for the comparison of VAS and WOMAC scores between groups were used for statistical analysis.
In an element for implantation in body tissue, particularly bone tissue, consisting of a biologically flawless material with a micro-pitted surface, the pores in the surface have a diameter many times smaller than has been previously known in order to permit the occurrence of such a tight and extensive boundary zone around the implanted element that this achieves reinforced and inextricable anchoring in the tissue. The pore diameter may be as little as about 10 nm and as large as a few multiples of the normal diameter of the cells in the tissue, preferably no larger than the cell diameter, i.e. about 1000 nm. Optimal results are obtained with pore diameters equal to or smaller than about 300 nm and a finely pored rutile layer has been found to give a particularly strong and durable joint with the growing tissue. Preferably at least one deposit of an agent facilitating and/or accelerating the growing-together process is arranged on or in the element. The element may be shaped with grooves, corrugations, channels etc. and be provided with an opening for tissue to grow through. The element is extremely suitable as anchoring device for a prosthesis or partial prosthesis and may be made integral therewith.
BACKGROUND: Artificial intelligence-based models might improve patient selection for liver transplantation in hepatocellular carcinoma. The objective of the current study was to develop artificial intelligence-based deep learning models and determine the risk of recurrence after living donor liver transplantation for hepatocellular carcinoma.
METHODS: The study was a single-center retrospective cohort study. Patients who underwent living donor liver transplantation for hepatocellular carcinoma were divided into training and validation cohorts (n = 192). The deep learning models were used to stratify patients in the training cohort into low- and high-risk groups, and 5-year recurrence-free survival was assessed in the validation cohort.
RESULTS: The median follow-up period was 59.1 (33.9-72.4) months. The artificial intelligence model (pretransplant factors) had an area under the curve of 0.86 in the training cohort and 0.71 in the validation cohort. The largest tumor diameter and alpha-fetoprotein level had the greatest Shapley Additive exPlanations values for recurrence (>0.4). The 5-year recurrence-free survival rates in the low- and high-risk groups were 92.6% and 45% (P < .001). In the second artificial intelligence model (pretransplant factors + grade), the area under the curve for the validation cohort was 0.77, with 5-year recurrence-free survival rates of 96% and 30% in the low- and high-risk groups (P < .001). None of the low-risk patients outside the Milan and University of California San Francisco Criteria had recurrence during follow-up.
CONCLUSIONS: The artificial intelligence-based hepatocellular carcinoma transplant recurrence models might improve patient selection for liver transplantation.
Heterotopic ossification (HO), defined as the formation of extraskeletal bone in muscle and soft tissues, is a diverse pathological process caused by either genetic mutations or inciting trauma. Fibrodysplasia ossificans progressiva (FOP) is a genetic form of HO caused by mutations in the bone morphogenetic protein (BMP) type I receptor gene activin A receptor type 1 (ACVR1). These mutations make ACVR1 hypersensitive to BMP and responsive to activin A. Hedgehog (Hh) signaling also contributes to HO development. However, the exact pathophysiology of how skeletogenic cells contribute to endochondral ossification in FOP remains unknown. Here, we showed that the wild-type or FOP-mutant ACVR1 localized in the cilia of stem cells from human exfoliated deciduous teeth with key FOP signaling components, including activin A receptor type 2A/2B, SMAD family member 1/5, and FK506-binding protein 12kD. Cilia suppression by deletion of intraflagellar transport 88 or ADP ribosylation factor like GTPase 3 effectively inhibited pathological BMP and Hh signaling, subdued aberrant chondro-osteogenic differentiation in primary mouse or human FOP cells, and diminished in vivo extraskeletal ossification in Acvr1Q207D, Sox2-Cre; Acvr1R206H/+ FOP mice and in burn tenotomy-treated wild-type mice. Our results provide a rationale for early and localized suppression of cilia in affected tissues after injury as a therapeutic strategy against either genetic or acquired HO.
Introduction: Intestinal flora and the translocation of its products, such as muramyl dipeptide (MDP), are common causes of sepsis. MDP is a common activator of the intracellular pattern recognition receptor NOD2, and MDP translocation can cause inflammatory damage to the small intestine and systemic inflammatory responses in rats. Therefore, this study investigated the effects of MDP on the intestinal mucosa and distant organs during sepsis and the role of the NOD2/AMPK/LC3 pathway in MDP-induced mitochondrial dysfunction in the intestinal epithelium. Methods: Fifty male Sprague Dawley rats were randomly divided into five treatment groups: lipopolysaccharide (LPS) only, 1.5 and 15 mg/kg MDP+LPS, and 1.5 and 15 mg/kg MDP+short-peptide enteral nutrition (SPEN)+LPS. The total caloric intake was the same per group. The rats were euthanized 24 h after establishing the model, and peripheral blood and small intestinal mucosal and lung tissues were collected. Results: Compared to the LPS group, both MDP+LPS groups had aggravated inflammatory damage to the intestinal mucosal and lung tissues, increased IL-6 and MDP production, increased NOD2 expression, decreased AMPK and LC3 expression, increased mitochondrial reactive oxygen species production, and decreased mitochondrial membrane potential. Compared to the MDP+LPS groups, the MDP+SPEN+LPS groups had decreased IL-6 and MDP production, increased AMPK and LC3 protein expression, and protected mitochondrial and organ functions. Conclusions: MDP translocation reduced mitochondrial autophagy by regulating the NOD2/AMPK/LC3 pathway, causing mitochondrial dysfunction. SPEN protected against MDP-induced impairment of intestinal epithelial mitochondrial function during sepsis.
Pimozide will be initiated at 1 mg twice daily then increased by 1mg twice daily every five days to 4 mg/day) for 45 days. End of study dose reduction will begin following the Final Outcome Measure Visit (Day 65). Pimozide will be titrated by reducing the dose by 1 mg twice daily every day to full discontinuation (over 2 days).
The term "folate" are B vitamins that include folic acid and any forms of active pteroylglutamates regardless of the reduction state of the molecule. Folates, or vitamin B9, are primarily hydrolyzed in the intestinal jejunum and the liver to the active circulating form of folate, I-methylfolate, with an intermediate stable form, 5,10-methylenetetrahydrofolate. Folic acid, including the reduced forms1 such as folinic acid, may obscure pernicious anemia above 0.1 mg doses, and must be administered under the supervision of a licensed medical practitioner.

The 1971, 1972, 1973, 1980, 1984, 2000, and 2010 Federal Register Notices addressed this concern while establishing that increased folate was proper therapy in megaloblastic anemias - specifically where homocysteine levels were elevated or risk of neural tube defects (NTDs) was at issue. The Federal Register Notice of August 2, 1973 (38 FR 20750) specifically states that: Dietary supplement preparations are available without a prescription (21 CFR 121.1134). Levels higher than dietary supplement amounts are available only with a prescription. Folic acid - including reduced forms, may be added to medical foods as defined in section 5(b) (3) of the Orphan Drug Act (21 USC 360ee(b)(3)), or to food (21 CFR 172.345).

* * *

1
     This product is a dietary supplement that - due to increased folate levels (AUG 3 1973 FR 20750), requires an Rx on the label because of increased risk associated with masking of vitamin B12 deficiency. As such, this product requires licensed medical supervision, an Rx status, and a National Drug Code (NDC) as required by pedigree reporting requirements.
Arthritis affects approximately 50 million adults in the United States (US), making it one of the most common causes of disability in this county. In addition, is associated with significant physical activity limitations, increased prevalence of obesity, decreased health related quality of life, and increased health care costs. Hispanics are affected by arthritis at a slightly lower age-adjusted rate compared to non-Hispanic whites and African Americans. However, compared to other groups, Hispanics have a higher prevalence of arthritis-attributed activity limitations (primarily related to OA), are less likely to receive hip replacement independent of health care access, and are less likely to receive knee replacement. In addition, there have been very few interventions to improve either medical or behavioral aspects of OA treatment recommendations among the Hispanic population. The study will developed and test a culturally appropriate Spanish educational materials and telephone scripts for the patient- and provider-based interventions and will test the patient and provider intervention in a group of Adult Hispanics with OA.
Disclosed is a system for recommending a health care wearable device and a health management application based on user preference. To this end, the present invention includes: a smart phone installed therein with an application capable of recommending a health care wearable device and a health management application based on user preference; and a center server cooperating with the application. When the application is executed, the center server transmits a survey for recommending a health care wearable device and a health management application based on user preference to the smart phone. The health care wearable device and the health management application based on user preference are provided to a user according to a result of the survey. The survey for recommending a health care wearable device based on user preference includes a use degree, functions, safety, materials, and a display of the wearable device, and a subjective evaluation of a user. The survey for recommending the health management application based on user preference includes participation, information, functions, aesthetic, and subjective evaluation of a user.
BACKGROUND: Low socioeconomic status is a risk factor for chronic obstructive pulmonary disease (COPD); however, the association between low household income and COPD in young populations remains unclear.
METHODS: We screened individuals aged 20-39 years who underwent the national health examination between 2009 and 2012 using the Korean National Health Information Database, which was searched until December 2019. We identified 5 965 366 eligible individuals, and 13 296 had newly developed COPD based on health insurance claims. We evaluated household income levels based on the health insurance premiums, categorised them into quartiles and 'Medical aid' (the lowest 3% income group), and assessed the annual income status from the preceding 4 years. Multivariate Cox proportional hazard models were used to estimate the adjusted HR (aHR) of risk factors for COPD.
RESULTS: In the Medical aid group, the incidence rate for developing COPD was 0.56/1000 person-years, with an aHR of 2.45 (95% CI 1.91 to 3.13) compared with that of the highest income quartile group. This association was prominent in consecutive recipients of Medical aid (aHR 2.37, 95% CI 1.80 to 3.11) compared with those who had never been Medical aid beneficiaries. Those who experienced a decline in household income between the previous (preceding 4 years) and baseline time points had an increased risk of developing COPD, regardless of previous income status.
CONCLUSION: Low household income was associated with an increased risk of developing COPD in the young population. This risk was augmented by sustained low income and declining income status.